Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience

S186the most frequent were keratopathy (83% and 83%), blurred vision (57% and 66%), dry eye (35% and 37%), and keratitis (20% and 23%).Among pts with ≥4 months of follow-up, mean time to first ocular AE was 39 (SD: 34) days.Most ocular AEs were managed by therapy hold (69%; of which 73% restarted belamaf ) and/or AE treatment (63%).The median dose hold due to ocular AEs was 43 days (physician-reported keratopathy: mild, 21 days; moderate/ severe, 56 days).In all pts, 39 (21%) had a derived tumor response based on serum free light chain levels, (partial response: 74%, very good partial response: 51%).For all pts, the estimated median DoR was 9.1 months, PFS 4.5 months, and OS 7.9 months.The 6-month DoR, PFS and OS rates were 57%, 46%, and 58%, respectively.Conclusions: Overall, belamaf was effective in the real-world setting in heavily pre-treated pts with RRMM and limited therapy options.The AE profile was consistent with DREAMM-2.Ocular AEs were manageable and despite their occurrence, a high percentage of pts remained on treatment, suggesting belamaf may fill an unmet need for triple-class refractory pts with RRMM.